神经元特异性烯醇化酶可能作为晚期mCRPC患者[18F]FDG/[68Ga]Ga-PSMA-11 PET不匹配表现的生物标志物
回顾性分析66例接受双显像[68Ga]Ga-PSMA-11与[18F]FDG PET/CT的晚期mCRPC患者,41例(62%)存在不匹配表现。不匹配组NSE血清水平(55.4±44.6 μg/l vs 18.5±8 μg/l,p<0.001)及ΔNSE(93.8±124.5% vs 2.9±39.5%,p<0.001)显著高于非不匹配组,PSA、ALP、GGT及其变化无显著差异。NSE可能作为不匹配表现的潜在实验室指标,尚待未来理想的前瞻性更大队列研究确认。
要点
- 66例晚期mCRPC中41例(62%)存在[18F]FDG/[68Ga]Ga-PSMA-11 PET不匹配表现。
- 不匹配组NSE及ΔNSE显著高于非不匹配组,PSA、ALP、GGT无显著差异。
- NSE截断值26.8 μg/l时敏感度78%、特异度96%;ΔNSE截断值+13.9%时敏感度84%、特异度75%。
核心结论
- 在晚期mCRPC患者中观察到,存在[18F]FDG高摄取且PSMA表达不足转移灶(PET/CT不匹配表现)者NSE绝对血清浓度及相对升高幅度显著更高。
- NSE可能作为[18F]FDG/[68Ga]Ga-PSMA-11不匹配表现的潜在实验室指标,但需未来理想的前瞻性更大队列研究确认该观察。
研究设计与样本
- 回顾性研究纳入66例晚期mCRPC患者,均在4周内完成[68Ga]Ga-PSMA-11与[18F]FDG双显像PET/CT,因转诊或接受[177Lu]Lu-PSMA-617放射性配体治疗。
- 检测PSA、NSE、GGT、ALP作为[18F]FDG/[68Ga]Ga-PSMA-11不匹配表现的指标,并分析[18F]FDG PET/CT前4±1周内的相对变化(ΔPSA、ΔNSE、ΔGGT、ΔALP)。
主要发现
- 41/66(62%)患者至少存在一处[18F]FDG/[68Ga]Ga-PSMA-11 PET/CT不匹配表现,其中13/41(32%)通过筛查发现、28/41(68%)在PSMA-RLT期间发现。
- 不匹配组NSE血清水平55.4±44.6 μg/l vs 非不匹配组18.5±8 μg/l,p<0.001;不匹配组ΔNSE 93.8±124.5% vs 非不匹配组2.9±39.5%,p<0.001。
- 血清PSA(p=0.424)、ΔPSA(p=0.417)、血清ALP(p=0.937)、ΔALP(p=0.611)、血清GGT(p=0.773)、ΔGGT(p=0.971)在不匹配组与非不匹配组间无显著差异。
- ROC分析中NSE的Youden指数最大值位于截断值26.8 μg/l(敏感度78%,特异度96%),ΔNSE位于+13.9%(敏感度84%,特异度75%)。
- 联合两参数的评分系统对[18F]FDG/[68Ga]Ga-PSMA-11不匹配表现的敏感度为90%、特异度为88%。
关键数值与推荐
- NSE截断值26.8 μg/l:敏感度78%,特异度96%。
- ΔNSE截断值+13.9%:敏感度84%,特异度75%。
- NSE与ΔNSE联合评分系统:敏感度90%,特异度88%。
临床怎么用
- 原文结论认为NSE可能作为[18F]FDG/[68Ga]Ga-PSMA-11不匹配表现的潜在实验室指标,但需未来理想的前瞻性更大队列研究确认。
局限性
- 原文结论指出该观察需在未来理想的前瞻性、更大患者队列研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [18F]FDG-avid lesions with low or no PSMA expression ([18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings on PET/CT) in the course of treatment. Those lesions are not affected by PSMA-RLT and a change in therapy management is needed. To enable early mismatch detection, possible blood parameters as indicators for the occurrence of [18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings on PET/CT were evaluated. METHODS: Retrospective study of N = 66 advanced mCRPC patients with dual [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT imaging within 4 weeks, who were referred for or received [177Lu]Lu-PSMA-617 radioligand therapy. Prostate-specific antigen (PSA), neuron-specific enolase (NSE), gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP) were tested as indicators for the occurrence of [18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings. Additional to absolute values, relative changes (ΔPSA, ΔNSE, ΔGGT, ΔALP) over a period of 4 ± 1 weeks prior to [18F]FDG PET/CT were analyzed. RESULTS: In total, 41/66 (62%) patients revealed at least one [18F]FDG/[68Ga]Ga-PSMA-11 mismatch finding on PET/CT. These mismatch findings were detected in 13/41 (32%) patients by screening for and in 28/41 (68%) patients during PSMA-RLT. NSE serum level (55.4 ± 44.6 μg/l vs. 18.5 ± 8 μg/l, p < 0.001) and ΔNSE (93.8 ± 124.5% vs. 2.9 ± 39.5%, p < 0.001) were significantly higher in the mismatch group than in the non-mismatch group. No significant differences were found for serum PSA (p = 0.424), ΔPSA (p = 0.417), serum ALP (p = 0.937), ΔALP (p = 0.611), serum GGT (p = 0.773), and ΔGGT (p = 0.971). For NSE and ΔNSE, the maximum value of the Youden index in ROC analysis was at a cut-off level of 26.8 μg/l (sensitivity 78%, specificity 96%) and at + 13.9% (sensitivity 84%, specificity 75%), respectively. An introduced scoring system of both parameters achieved a sensitivity of 90% and a specificity of 88% for the occurrence of [18F]FDG/[68Ga]Ga-PSMA-11 mismatch. CONCLUSION: We observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [18F]FDG-avid and insufficient PSMA expressing metastases ([18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings on PET/CT) in our cohort. NSE might be used as a potential laboratory indicator for [18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings, if this observation is confirmed in future, ideally prospective, studies in larger patient cohorts.
引用
- Rosar F, Ribbat K, Ries M, et al. Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. EJNMMI Res. 2020. PMID: 32449086. doi:10.1186/s13550-020-00640-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。